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Abstract
Induction of protein-protein interactions is a daunting challenge, but recent studies show promise
for small molecules that specifically bring two or more protein molecules together for enhanced or
novel biological effect. The first such bifunctional molecules were the rapamycin- and FK506-
based “Chemical Inducers of Dimerization”, but the field has since expanded with new molecules
and new applications in chemical genetics and cell biology. Examples include coumermycin-
mediated gyrase B dimerization, proteolysis targeting chimeric molecules (PROTACS), drug
hybrids, and strategies for exploiting multivalency in toxin binding and antibody recruitment. This
review discusses these and other advances in the design and use of bifunctional small molecules,
and potential strategies for future systems.
Introduction
Given the importance of protein-protein interactions in mediating diverse intracellular
processes, inhibition of these interactions with small molecules is one of the “holy grails” of
pharmacology (1). However, because of the large, complex surfaces involved in these
interfaces, there has been only limited success towards this goal, with some notable
exceptions (reviewed in (2–4)). But the opposite challenge – small molecule mediated
dimerization or oligomerization of proteins – has progressed much further, relying on
bifunctional ligands. Here, we discuss efforts to bring proteins together to induce a specific
biological effect.
A bifunctional small molecule can be as simple as a natural product that interacts with two
protein molecules simultaneously, such as the antibiotic coumermycin (see below) or the
fungal toxin brefeldin A, which inhibits the small G-protein Arf by stabilizing an inactive
complex with GDP-Arf and a guanine nucleotide exchange factor (5). However, the
majority of successful, synthetic, bifunctional molecules consist of two protein-binding
moieties joined via a linker of appropriate length (Figure 1). If these moieties are identical
(homobifunctional), the molecule will dimerize two identical protein monomers, but if the
moieties differ (heterobifunctional), two different proteins can be brought together. The
applications of these molecules are as varied as their design. For example, the juxtaposition
of two or more proteins can cause ligand-independent activation of receptors or bipartite
transcription factors. It can sequester one protein in the subcellular location of the other,
target a protein for destruction, or create a binding surface recognized by other proteins,
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leading to positive or negative regulation of signaling. Bifunctional molecules can
specifically localize toxins, and “drug hybrids” (see below) can influence the activity of two
proteins without forming dimers. Notably, in most cases these effects are tunable (by
varying small molecule concentration), and reversible (on removal of drug).
The concept of “chemical inducers of dimerization” (CID) (6) dates to early work by the
Schreiber and Crabtree groups (7). These labs took advantage of the specific binding of the
natural product FK506 to the protein FKBP12 (FK506 binding protein 12). Normally, this
drug acts as a natural heterodimerizer, causing the recruitment of the protein phosphatase
calcineurin to the FK506-FKBP12 complex. However, an artificial dimer of FK506 named
FK1012 instead promotes FKBP12 homodimerization, allowing small-molecule controlled
dimerization of signaling proteins (initially, the cytoplasmic domains of the T-cell receptor ζ
subunit) fused to FKBP12 monomers (7). Similarly, the natural product heterodimerizer
rapamycin promotes interaction between FKBP12 and the FKBP-rapamycin-binding (FRB)
domain of mTor. Thus, rapamycin can be used to heterodimerize protein fusions containing
FKBP and FRB domains (8). Alternatively, heterodimerization can be induced with an
FK506-cyclosporin fusion, which brings together FKBP12 and cyclophilin proteins (9).
Subsequently, variants of these molecules were engineered to bind mutant versions of their
target proteins, creating orthogonal dimerizer systems that have been used in transgenic
mice (10,11), although recent evidence suggests that both mutant and wild-type FRB-protein
fusions are destabilized (12). Dimerization “kits” based on these systems have been
developed by ARIAD Pharmaceuticals, Inc (http://www.ariad.com/wt/page/regulation_kits).
The diversity of applications of FKBP-based CID has been comprehensively reviewed
recently (13). One noteworthy variant is the “yeast three-hybrid” system (Figure 2) for
identifying protein targets of a small molecule (reviewed in (14)). Similar to the yeast two-
hybrid method for detecting protein-protein interactions, this approach involves bringing a
transcriptional activation domain fusion into contact with a DNA-binding domain fusion,
leading to transcription of a reporter gene. Rather than relying on protein-protein
interactions of the two fused proteins to activate transcription, the three-hybrid approach
uses a CID, with a moiety that binds to the DNA-binding domain fusion, and a moiety that
binds to the activation domain fusion. If the latter moiety is a small molecule of unknown
target, a library of activation domain-cDNA fusions can be used to identify possible targets.
The first proof-of-principle of this system used the synthetic glucocorticoid dexamethasone
fused to FK506 to bring FKBP12 and glucocorticoid receptor fusions together (15). But
FKBP12/FRB/cyclophilin are not the only possible targets in three-hybrid, or indeed in
other, CID systems; other classes of small-molecule dimerizers have been described and
offer viable alternatives to traditional CID. Given the recent review of FK506/rapamycin-
based CIDs (13), we focus on those bifunctional molecules that do not incorporate FK506 or
rapamycin derivatives.
We discuss here three classes of bifunctional molecules, grouped according to their
increasing potential for use in whole organisms: those used to date solely in cell-free studies;
those used in cells, but requiring genetic manipulation of one or more target proteins; and
finally those that target endogenous proteins, i.e., do not require genetic manipulation.
Cell-free studies
Several intriguing small molecule dimerizer systems have unfortunately not yet progressed
beyond in vitro experiments (Figure 3). In one of the first departures from FK506/
rapamycin-based CID, Kopytek et al. developed, and studied in vitro, a dimerization system
based on methotrexate (MTX) (16). This folate analog binds exceptionally strongly to
dihydrofolate reductase (DHFR), inhibiting the function of this key enzyme in nucleotide
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biosynthesis. Since extensive structural information on the MTX-DHFR interaction was
available, these authors were able to choose a region of MTX that was not essential for
binding, and link it to the same site on a second MTX molecule via an appropriate length
linker. The bisMTX 1 caused a concentration-dependent increase in dimerization of purified
DHFR. Moreover, binding did not decrease at high bisMTX concentrations, and was tighter
to bisMTX than monomeric MTX, suggesting a cooperative binding effect. MTX has since
found application as one half of heterobifunctional molecules in other systems (see below).
Very recently, a conceptually similar homodimerizer system was presented (17). Human
nonpancreatic phospholipase A2 (PLA2) is an enzyme involved in arachidonate and
lysophospholipid metabolism, implicated in inflammatory processes. The flat i-face of the
enzyme interacts tightly with the phospholipid bilayer. Using a known i-face-binding indole
inhibitor of PLA2, Zhou et al. constructed homobifunctional bis-indole ligands with various
linkers that were capable of dimerizing purified enzyme. The most effective of these (2)
inhibited PLA2 activity five times more effectively than a monomeric indole, offering
promise not only as a therapeutic for PLA2-overexpressing rheumatoid arthritis, but also as
a novel CID system.
Two other examples build on the CID paradigm, but extend it from a one-small-molecule/
two-protein (ternary) system to a multivalent one, leading to a tighter protein-protein
interaction. Both cholera toxin B and the human innate immune system protein serum
amyloid P (SAP) component exist as pentamers; cholera toxin could potentially be
detoxified by aggregation with SAP. Liu et al. reasoned that each cholera toxin pentamer
could bind five bifunctional ligands that would each present a moiety to SAP (or vice versa),
creating a high avidity interaction (18). Using structure-based design, and known ligands for
SAP (D-proline) and cholera toxin (m-nitrophenyl-α-D-galactopyranoside, MNPG), these
authors produced a reagent (3) that bound SAP and cholera toxin simultaneously. It also
inhibited the binding of cholera toxin to immobilized receptor more effectively than MNPG
alone in a SAP-dependent manner.
In a similar vein, Solomon et al. (19) targeted Shiga toxin to SAP. However, rather than
relying on binding of five dimerizer molecules, they constructed a five-armed dendrimer (4),
with each linker arm ending in a heterobifunctional “glycocluster.” Each glycocluster
consisted of a Shiga toxin-binding trisaccharide and a SAP-binding cyclic pyruvate of
glycerol. In a Shiga toxin binding competition assay, the dendrimer disrupted Shiga toxin-
target binding better than the monomer glycocluster, and addition of SAP further disrupted
binding in each case, providing proof-of-principle of this multivalent toxin-SAP dimerizer
as a potential therapeutic lead.
Techniques requiring genetic manipulation
Dimerization techniques that have demonstrated function in living cells are substantially
closer to whole-organism or clinical deployment than those tested only in vitro. However,
many approaches (including the original CID) require genetic manipulation to create
chimeric proteins incorporating the dimerizer target and the protein of interest (Figure 4).
For this reason, the potential clinical applications of the following are limited, although they
are certainly powerful research tools.
One of the first examples of the CID paradigm to go beyond FK506/rapamycin took
advantage of the ability of the well-studied, non-toxic natural product coumermycin (5) to
dimerize bacterial DNA gyrase B (GyrB) domains (20). Farrar et al. (21) used coumermycin
to form homodimers of Raf-1-GyrB fusions. These homodimers could activate MEK
(although surprisingly not all downstream signaling activities (22)), without the usual Ras-
dependent membrane localization, thus providing the first evidence of Raf activation
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independent of Ras. High coumermycin concentrations attenuated this activation, suggesting
that binding site saturation leads to dissociation of the dimers, which was confirmed with
novobiocin, a “monomeric” form of coumermycin that does not dimerize Raf-GyrB.
Interestingly, a similar system was later used to show that coumermycin-mediated Ras
dimerization could activate Raf (23).
Subsequently, the GyrB/coumermycin system has been used to activate several signaling
pathways, offering more specific control than receptor activation, which tends to feed into
multiple signaling pathways. Most work has been done on Jak/Stat signaling. The system
has been used to dimerize Janus kinases Jak2 (24,25) and Tyk2 (26) to dissect receptor-
dependent and -independent signaling. Downstream, coumermycin-mediated dimerization of
Stat3-GyrB fusion proteins activated transcription, short-circuiting a normally IL-10
dependent growth inhibition (27); in combination with loss-of-function (dominant negative)
experiments, the Stat3-GyrB dimer enabled elucidation of the role of p19INK4D in this
process (28). However, Stat5-GyrB dimerization could not confer IL-3 independence to cells
except in the presence of activated Ras, highlighting the dependence of Stat5 signaling on
Ras (29).
A number of membrane-bound receptors have been fused to GyrB. Dimerization of the
lymphocyte adhesion molecule L-selectin via fusion of GyrB to its intracellular domain and
coumermycin treatment caused increased binding to an extracellular ligand, which is an
important part of the inflammatory response (30). Granulocyte colony stimulating factor
receptor-GyrB dimerization has been suggested as a potentially viable method of promoting
growth of transduced cells in gene therapy, due to the low toxicity of coumermycin (31). In
addition, dimerization-mediated activation of vascular endothelial growth factor receptor
(VEGFR) allowed analysis of receptor subtypes 1 or 2 separately (32), which was
previously only possible by transfection into cell types lacking VEGFR expression (and thus
expression of possible downstream signaling components). Coumermycin-mediated
dimerization/oligomerization of the platelet activating factor receptor allowed analysis of
oligomerization-driven receptor internalization with and without agonist (33).
The system has also been used to confirm the importance of dimerization for intracellular
signal transducers. After observing that the mitogen-activated protein kinase kinase kinase
ASK1 is naturally activated by dimerization, Gotoh and Cooper confirmed this phenomenon
using ASK1-GyrB (34). Sanz et al. used a TRAF6-GyrB fusion to show that dimerized
signal transducer TRAF6 could interact with protein kinase C ζ (35), and Ung et al.
demonstrated the importance of protein kinase R dimerization (usually RNA-mediated), by
replacing the RNA binding domains with GyrB, and showing coumermycin-dependent
activity (36).
Finally, this system has been adapted to control gene expression (37): homodimers of the
bacteriophage λ repressor, formed by coumermycin-driven dimerization of λ repressor-GyrB
fusions, bind to DNA. When a transcriptional activation domain is also fused to these
proteins, coumermycin-dependent transcriptional control is possible. Most interestingly,
however, is that addition of novobiocin rapidly shuts off coumermycin-driven transcription,
offering a powerful on/off gene regulatory system. As in other studies on this well-used
dimerization system, strengths of this work are that both coumermycin and novobiocin are
well tolerated in vivo, and that GyrB has no known function in mammalian cells, offering
promise that this could be a component of regulated gene therapy systems. In addition, it
will be interesting to see if recently-reported, simplified coumarin dimers will be amenable
to use in GyrB dimerization systems (38).
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An alternative, covalent dimerization system was developed by Athavankar and Peterson
(39), using unmodified biotin as the small molecule inducer. This system relies on three
proteins: the BirA biotin ligase from Escherichia coli, one target protein fused to
streptavidin, and the other target protein fused to AviTag, a 15-mer substrate of BirA. BirA
catalyzes the biotinylation of lysine in the AviTag (an otherwise extremely rare lysine
modification), yielding adduct 6. The biotinylated AviTag fusion protein then binds the
streptavidin fusion protein via the extremely high-affinity avidin-biotin interaction. These
authors demonstrated the feasibility of this system in a yeast gene expression activation
assay similar to a three-hybrid approach: they used a DNA-binding LexA domain fused to
streptavidin, and a B42 transcriptional activation domain fused to green fluorescent protein
(GFP) and AviTag. Addition of biotin caused a marked increase in lacZ expression driven
by the B42 activator, which was saturable at high biotin concentrations. Unfortunately, the
advantages of covalent modification offered by this system are largely mitigated by the need
to introduce three separate transgenes. Nonetheless, it has recently found application in two
gene expression control systems for mammalian cells. The first fuses the AviTag to the
VP16 transcriptional activator. In the presence of BirA and biotin, this fusion interacts with
a streptavidin-DNA binding module, activating transcription (which can be shut off by
treatment with an antibiotic that releases the DNA binding module from the DNA) (40).
Conversely, the second system is built around an AviTag-DNA binding module. In the
presence of biotin and BirA, a streptavidin-KRAB transrepression domain fusion is
recruited, shutting down transcription. This system can be titrated with excess biotin (41).
The Peterson group has also devised novel heterobifunctional reagents for gene expression
regulation, in the context of yeast three-hybrid studies (42,43). One of these molecules (7)
combines estrone, a ligand of the estrogen receptor (ER), with biotin, allowing recruitment
of streptavidin-B42 to ER-LexA DNA-binding fusions. Along with earlier, FKBP12-based
yeast three-hybrid systems, this work complements that of the Cornish laboratory, which
synthesized heterobifunctional molecules containing dexamethasone at one end and MTX at
the other, allowing recruitment of a glucocorticoid receptor-B42 fusion to a DHFR-LexA
fusion (44). They have since modified this system to reduce potential MTX toxicity (but
unfortunately losing some activity) by replacing it with the bacterial-specific DHFR
inhibitor trimethoprim (45). Most recently, these latter two systems were combined to
demonstrate their use as part of a five-input logic circuit (46). The output of the circuit (lacZ
transcription) is predictably controlled by the binary variables of presence/absence of
unmodified MTX (which inhibits the system in high concentrations), dexamethasone-MTX,
dexamethasone-trimethoprim, glucose, and galactose (since the GAL1 promoter that controls
the transgene expression is active in the presence of galactose and repressed in the presence
of glucose). This demonstration opens new avenues for the use of heterobifunctional small
molecules in biological systems engineering.
The Cornish laboratory has also described a specialized twist on their yeast three-hybrid
system termed “chemical complementation” (47). They wished to screen the activity of
enzymes, so they introduced a cephalosporin unit into the linker of their dexamethasone-
MTX molecule (8). In the presence of cephalosporinase, the molecule was cleaved, ablating
the transcriptional response (lacZ gene product) (47). Subsequently, they successfully used
this system to screen a mutant library for β-lactamase mutants that could be involved in
resistance to the cephalosporin cefotaxime (48). In a reverse application, they synthesized
dexamethasone linked to cellobioside and MTX linked to lactosyl fluoride, and screened for
glycoside linkage formation by glycosynthases, a class of artificial glycosidases (49,50). In
the presence of an appropriate glycosynthase, transcriptional activation of a LEU2 gene
occurred, as evidenced by increased survival on leucine dropout medium. This system has
been successfully applied to identify a novel glycosynthase (51).
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MTX forms one half of yet another dimerizer system, this one developed by the Johnsson
lab (52), which has linked it to an O6-benzylguanine (BG) derivative. BG is a substrate for
the enzyme O6-alkylguanine-DNA alkyltransferase (AGT, termed “SNAP-Tag”), which
covalently binds to it via an active site cysteine. This substrate-enzyme system has been
widely used to label fusion proteins with fluorophores for imaging purposes (53,54). In the
dimerizer context, however, the MTX-BG heterobifunctional molecule (9) connected with
either an alkyl or polyethylene glycol linker successfully caused a three-hybrid interaction
between AGT-LexA and DHFR-B42 fusions, leading to transcriptional activation. In a
logical extension of this work, the same group has created bisBG derivatives (with 3
different linker lengths, all functional) capable of covalently dimerizing two AGT-protein
fusions (55). This doubly covalent bonding is very appealing, allowing immunoblot
evaluation of dimerization efficiency, and “freezing” protein-protein interactions for
detection. The authors demonstrated this in two ways: firstly by targeting AGT fusions to
different cellular compartments, resulting in much less dimer formation than with similar
fusions expressed in the same compartment; and then by showing increased interaction
between AGT-FKBP12 and AGT-FRB in the presence of rapamycin. However, the
homobifunctional nature of these molecules limits current utility. This group has recently
described the “CLIP-tag,” an engineered AGT mutant that specifically binds O2-
benzylcytosine (56); we anticipate that future work will yield a BG-benzylcytosine
dimerizer.
Techniques not requiring genetic manipulation
The appeal of developing bifunctional small molecules that can exert their effect without the
need for genetic manipulation of the treated cells (Figure 5) lies in the fact that we cannot
readily genetically manipulate the cells of patients. Two of the earliest examples of such
molecules focused on providing selectivity to compounds that were previously non-
selective, both targeting the intracellular estrogen receptor (ER).
First, Rink and co-workers described a system (10) in which a DNA-alkylating agent was
conferred with improved selectivity by tethering it to a moiety that recognizes the ER (57).
Nitrogen mustards have long been known to alkylate DNA in a non-specific manner,
resulting in potent if indiscriminant cytotoxicity. By contrast, 2-phenylindoles bind
specifically to their target, the ER, which is over-expressed in many breast and ovarian
tumors. Comparisons were made between toxicity towards the ER-positive MCF7 cell line
and the ER-negative MDA-MB-231 cell line, both from breast tumors. Compounds with no
affinity for the ER showed similar effects on both cell lines. The synthesized bifunctional
molecules that did show affinity for the ER demonstrated higher toxicity for the MCF7 cells
than for the MDA-MB-231 cells, indicating that the presence or absence of ER was a
contributing factor. Treatment with estradiol following application of the drug resulted in
lower toxicity towards MCF7 cells, further supporting the role of ER binding in providing
the selectivity. The authors propose various explanations for this selectivity, the most
plausible of which is the apparent shielding of the damaged DNA from repair enzymes by
the proximity of the 2-phenylindole-bound ER. These authors have subsequently optimized
their constructs, varying linker length and using estradiol as the ER ligand (58,59).
Improving the selectivity of mustard-based DNA alkylators has also been achieved by
linking them to DNA minor groove binders (60).
The second early targeting of the ER involved modifying the toxicity of geldanamycin, a
natural product that normally binds to the molecular chaperone Hsp90 and induces
proteasome-dependent degradation of a range of proteins. This unfortunately results in non-
selective toxicity and undesirable side effects. A strategy to harness this toxicity towards a
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particular target, the ER, required the synthesis of a geldanamycin derivative attached to a
molecule that would bind to the ER, in this case, estradiol (61).
In MCF7 cells, geldanamycin induced rapid degradation of ER, HER-2, Raf-1 and IGF1R.
Construct 11 was found to induce degradation of the ER, but had no effect on levels of
Raf-1 or IGF1R, and the rate of HER-2 degradation was partially attenuated, although the
activity of the construct was highly dependent on the type and length of linker. A similar
approach was taken in a more recent report, wherein estradiol was used to target a
photoactivatable porphyrin to ER-positive cells, resulting in selective killing of the targeted
cells after exposure to red light (62). These studies demonstrate that the selectivity profile of
a toxic compound can be vastly improved by linkage to a targeting moiety.
A similar approach was used to target degradation of the androgen receptor (AR), a nuclear
receptor implicated in progression of prostate cancer. In that instance, the geldanamycin
hybrid was prepared with the AR ligand testosterone (63). Again, biological activity was
linker-dependent, but one bifunctional molecule was found to have cytotoxicity towards
LNCaP prostate cancer cells comparable with geldanamycin itself. Testing this molecule
against a range of cell lines showed that, in AR-dependent cells, it had an IC50 comparable
to that of geldanamycin. By contrast, in AR-independent cells, the bifunctional construct
was found to be more than ten times weaker than geldanamycin, thus providing a promising
therapeutic window.
One area in which heterobifunctional small molecules have played an important role is
ubiquitin-dependent proteolysis: poly-ubiquitination of a given protein results in degradation
by the proteasome in a process that occurs as part of normal cellular homeostasis. Ubiquitin
is a small, highly conserved protein that is attached to lysine residues on proteins targeted
for degradation through the action of ubiquitin-activating enzymes (E1), ubiquitin-
conjugating enzymes (E2) and ubiquitin-protein ligases (E3), the last of which binds directly
to the substrate protein and thus confers the specificity of ubiquitination. Successive
conjugation of ubiquitin to previously added ubiquitin units on the targeted protein results in
a polyubiquitin chain that is recognized by the 26S proteasome, ultimately leading to
degradation of the target protein.
A bifunctional molecule capable of hijacking this system and selectively degrading targeted
proteins is a powerful tool for chemical genetics. Small molecule-induced knockdown
provides a new method of learning about the role and function of proteins through controlled
knockdown. This is particularly useful for studying proteins essential for development that
cannot be constitutively knocked out. PROteolysis TArgeting Chimeric molecules
(PROTACS) make use of the ubiquitin-proteasome pathway and allow for such temporally
controlled elimination of proteins in a post-translational manner, operating through
simultaneous binding of a target protein and an E3 ligase (Figure 6).
The initial proof-of-concept (64) focused on degrading methionine aminopeptidase-2
(MetAP-2), which cleaves N-terminal methionine residues from nascent polypeptides.
Ovalicin is a member of the fumagillin class of angiogenesis inhibitors, known to bind to the
active site of MetAP-2 (65), and was thus chosen as one of the two heads in “PROTAC-1”
(12). Ovalicin was linked to the E3-ligase binding sequence of IκBα, reported to bind to the
SCFβ-TRCP complex that induces ubiquitination. After demonstrating that PROTAC-1 binds
to MetAP-2 in vitro and recruits it to the SCFβ-TRCP E3 ligase, Sakamoto et al. (64) then
showed that MetAP-2 is indeed ubiquitinated, and that this is dependent on the presence of
PROTAC-1. When tested in Xenopus egg extracts, a PROTAC-1-MetAP-2 complex was
degraded within thirty minutes, while free MetAP-2 levels remained constant. Saliently,
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addition of proteasome inhibitors blocked this degradation, indicating that PROTAC-1 was
acting via the endogenous ubiquitin-proteasome pathway.
From this in vitro beginning, the PROTAC concept has progressed towards potential use as
a therapeutic: a subsequent paper used estradiol and dihydroxytestosterone-based
PROTACS to degrade the estrogen and androgen receptors, respectively (66), both of which
are implicated in certain types of cancer. The authors microinjected a PROTAC into cells,
with the result that degradation of an AR-GFP fusion protein could be monitored by the loss
of fluorescence. Cell permeability issues related to the phosphorylated IκBα moiety were
circumvented in a third paper (67), where the bifunctional molecule incorporated a
polyarginine chain to mimic the HIV Tat protein (known to act as a molecular transporter)
and used a 7-amino acid recognition sequence for the von Hippel-Lindau tumor suppressor
protein (VHL) as the E3-ligase binding domain. This PROTAC-5 (13) was added to
HEK293 cells stably transfected with an AR-GFP fusion protein, the only genetic
manipulation involved in this system and used purely for visualization purposes. The
proteasome-mediated degradation of AR-GFP in these cells was observed through loss of
GFP fluorescence, representing a major step towards therapeutic utility.
Subsequently, the 7-amino acid VHL recognition sequence has been simplified to a highly
cell-permeable pentapeptide (68), and the first fully genetic manipulation-free system has
been reported (69). The aryl hydrocarbon receptor has also been targeted for degradation by
14, enabling future study of the function of this protein, specifically as related to tumor
development (70,71). Most recently, our group has described an all small-molecule (non-
peptidic) PROTAC targeting the AR for degradation using an MDM2-binding nutlin
derivative as the E3 ligase-binding moiety (72).
Recent contributions to the field of heterobifunctional molecules have tapped into the power
of the immune system, a strategy raised in the early 1990s (73,74) (Figure 7). Kiessling and
co-workers (75) have synthesized a small molecule capable of recruiting a common human
antibody exclusively to cells expressing a cell-surface receptor that is over-expressed on
cancer cells and largely absent from normal tissue, the αvβ3 integrin receptor. This
recruitment renders the cell susceptible to attack by the immune system, leading to
elimination of specifically targeted cells.
As an initial step, two ligands exhibiting high potency (low nM range) and good specificity
for αvβ3 were chosen to form one end of the bifunctional molecule (75). Crystal structures of
one ligand (the cyclic RGD peptide) bound to αvβ3 allowed the design of linker-
incorporating derivatives that would not perturb binding. The other end of the molecule
required the epitope component (see Figure 7). The carbohydrate-based α-Gal epitope is
known to be immunogenic, though it is not displayed in human cells. High levels of anti-Gal
antibody are, however, present in humans, due to exposure to α-Gal-displaying bacteria. An
appropriately functionalized trisaccharide moiety was chosen for antibody recruitment.
Both conjugates prevented interaction between cells expressing αvβ3 and a known protein
ligand for that receptor, fibrinogen, with IC50 values in the nanomolar range (75). By
contrast, the IC50 values calculated for cells expressing αvβ5 was in the micromolar range,
indicating that the bifunctional molecules possessed the required specificity. The conjugate
15 was then shown to bind simultaneously to both αvβ3-positive cells and anti-Gal IgG from
human serum, demonstrating the potential for this concept to provide new therapies that
specifically target tumor cells. A follow-up report confirmed that the conjugates were
cytotoxic only to cells expressing high levels of αvβ3 receptors (76). Cells with only low
receptor levels survived, due to an inability to form multivalent antibody interactions with
the required avidity.
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In a similar approach, O’Reilly et al. (77) recently linked the antigen nitrophenol (for which
endogenous antibodies exist in humans) to a modified trisaccharide ligand for CD22, a B
cell surface protein that can be targeted in B cell depletion therapy. The resulting
bifunctional molecule (16) was able to form complexes between decameric anti-nitrophenol
IgM and clusters of CD22 molecules both in vitro and on B cells, offering an attractive,
multivalent way of binding these low-affinity receptors, potentially leading to B cell killing
by the immune system.
Using a different approach, Matsuda et al. (78) investigated lymphocyte-endothelial cell
interactions, which are potentially important for anti-inflammatory and antimetastatic
therapeutic interventions. Both carbohydrate-binding selectins and protein-binding integrins
are involved in these interactions, so these authors created a chimeric molecule (17) fusing
the P-selectin-binding tetrasaccharide known as sialyl Lewisx with a flexible KG dipeptide
linker and the integrin-binding peptide RGDS (78). As well as binding integrin β1 and P-
selectin independently, this compound could form a ternary complex with both immobilized
P-selectin and integrin β1 in solution. In a preliminary functional test, the heterobifunctional
construct inhibited T-cell binding to collagen-coated plates, while the individual tetrapeptide
and tetrasaccharide constituents did not, suggesting that this kind of double-headed molecule
could have useful biological applications.
The Portoghese lab, moving towards the clinic, and following a long line of research on the
roles of opioid receptors (79), has reported the identification of heterobifunctional molecules
that are not only fifty times more potent than morphine, but that do not induce the same
dependence and tolerance as the well-known drug of addiction when administered to mice
(80). The so-called “MDAN” ligands (μ-δ agonist-antagonist) comprise an agonist of the μ
opioid receptor (oxymorphone) and an antagonist of the δ receptor (naltrindole). MDAN-21
(18), containing a 21-atom linker between the two pharmacophores, produced neither
tolerance nor dependance, but shorter linkers produced either both responses or tolerance
alone. The authors conclude that this biological effect is a result of the heterodimer formed
between the μ and δ receptors. Further, the potency of these compounds holds promise for
developing new pain-killers with improved side-effect profiles.
Neurodegenerative diseases such as Parkinson’s and Alzheimer’s operate by complex
mechanisms that are not yet fully understood, leading many to believe that a cocktail of
drugs may be necessary to achieve improved therapeutic outcomes (81). Since an alternative
to multiple drugs is a single drug agent that performs multiple therapeutic roles, researchers
in this and other fields are turning towards bifunctional molecules (Figure 8). Unlike many
other bifunctional molecules discussed in this review, these “drug hybrids” tend to
incorporate two functional elements into a single framework, resulting in smaller drugs than
the linking of two distinct fragments through a long linker. While this strategy is suitable for
achieving two distinct biological effects, it is unlikely to succeed in inducing formation of a
ternary complex with two biomolecules.
Levels of both monoamine oxidase (MAO) activity and iron are increased in the brain as a
result of Parkinson’s disease. Exploiting the finding that neuroprotection could be obtained
from 8-hydroxyquinoline-based iron chelators as well as from MAO-inhibiting
propargylamines, Youdim and co-workers combined these two components into a series of
molecules that possessed both properties. The best results were obtained for 19, which
exhibited good iron chelation levels in vitro and provided neuroprotection against oxidative
stress in P19 cells, despite a relatively weak ability to inhibit MAO activity (82,83).
Similarly, work on Alzheimer’s disease has combined the nitric oxide mimicking potential
of nitrate esters with a heterocyclic scaffold present in the simple neuroprotective γ-
aminobutyric acid receptor agonist clomethiazole. Nitric oxide signaling controls many
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processes in the central nervous system, and is thus a factor in neurodegenerative diseases.
The product of these bifunctional endeavors is GT 1061 (20), an orally available and blood-
brain barrier crossing molecule that has been extensively studied in rats (84) and has been
approved for Phase I clinical trials for Alzheimer’s disease (85).
Examples of drug hybrids for malaria treatment were recently highlighted in C&E News
(86). As with the neurodegenerative treatments discussed above, these hybrids do not form
ternary complexes with two separate biomolecules, but act as bifunctional molecules with
two different targets. Whether the hybrids remain intact in vivo can be unclear, although
they may have advantages over drug cocktails in terms of dosing, delivery and localization.
Using this strategy, several different bifunctional molecules targeting malaria have been
produced. Exploitation of the synergy between fast-acting artemisinin and slow-acting
quinine provided a hybrid (21) with a lower IC50 than either drug alone or both drugs
together, in two different strains of the Plasmodium falciparum parasite (87) (a related
approach was reported earlier (88)). Also, the Peyton lab has connected the quinoline moiety
of the known antimalarial chloroquine to a tricyclic “reversal agent” known to block the
action of a transporter that removes chloroquine from its site of action. This resulted in a
hybrid (22) that demonstrated potent growth inhibition of P. falciparum in culture and
promising early results in mice (89). Application of drug hybrids in the field of HIV
treatment was reviewed recently (90).
Conclusions
The past decade has seen significant advances in the use of heterobifunctional small
molecules. While the well-established FK506/rapamycin systems have been most
extensively studied and validated, the strategies reviewed here also represent valuable
additions to the arsenal of those working at the chemistry-biology interface. The breadth of
biological problems to which these molecules have been applied demonstrates their potential
to tackle many outstanding questions in biomedical research, and to move towards
therapeutic applications in the future. Some of the lessons learned in the research discussed
above can help lead this field into the future.
The benefits of a modular synthesis cannot be underestimated: fine-tuning the properties of
either end of a heterobifunctional molecule can become tedious if a lengthy linear synthetic
route is taken. Many of the reported systems make use of small molecules already known to
bind to a specific protein, and thus developing a full synthesis from scratch is rarely
necessary. Indeed, the wealth of literature from drug discovery programs highlights the
many proteins that can be readily targeted in future studies with heterobifunctional
molecules. Further, it is worth noting that small molecules need not necessarily bind to the
active site of proteins to be useful: any high-affinity ligand is capable of promoting the
desired interaction. It is also appealing to envisage a “toolbox” of dimerizing reagents. Once
a ligand for a specific protein is discovered, incorporating it into variants of the
heterobifunctional molecules described above may provide useful information about the role
of that protein. Such an approach would build towards libraries of bifunctional molecules
targeting large sections of the proteome, enabling chemical genomic degradation,
mislocalization, sequestration, or even rapid screens of potential synergism.
Linking two molecule fragments, however, provides its own challenges. The site through
which the linker is tethered can be crucial. In particular, great care must be taken to avoid
disrupting pharmacophores or inducing a change in conformation that compromises binding
affinity. Although linker composition is frequently governed by synthetic ease and
compound availability, identifying the optimum linker length is vital (this is typically
determined empirically, with minor length differences able to cause significant differences
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in activity). Linkers must be long enough and flexible enough to enable both ends of the
molecule to interact freely with their protein targets, but short enough to ensure that the
proteins are close enough for whatever dimerization effect is desired. Linkers should not be
overly hydrophobic (which would promote self-interaction in aqueous solution), or too
reactive (esters, for instance, could be cleaved in vivo). One of the major drawbacks of
bifunctional molecules as potential therapeutics is their large size. Bulky molecules are not
only likely to be insoluble and therefore orally unavailable, but also prone to be membrane
impermeable, leading to correspondingly poor pharmacokinetics. Minimizing ligand and
linker size, and structure optimization before clinical deployment of bifunctional molecules
in future will be key to overcoming these very real concerns. The successes of drug hybrids
show that this is possible.
There is great potential to combine elements of some of the systems described here (and
elsewhere (13)) to facilitate the targeting of related proteins, or to induce formation of a
different ternary complex to achieve a different biological result. New combinations will
inevitably produce new ways of obtaining improved drug selectivity, a key feature in much
of this research, moving towards Paul Ehrlich’s “magic bullet” concept of directing a toxin
to the origin of a disease. Simultaneously, further improvements in potency can be expected,
as exemplified by the drug hybrid approaches and also through minimizing loss of drug to
other parts of the cell. Part of the selectivity of these bifunctional molecules derives from the
need to establish two separate interactions, but this can also represent a drawback: the
affinity of each interaction must be strong enough to sustain the desired biological effect.
Covalent binding, in this context, can be highly beneficial, as it eliminates concern over at
least one binding affinity (91), as demonstrated in the cases of the SNAP-Tag and the BirA
biotin ligase systems. New technologies may find useful applications in this respect: the
chloroalkane HaloTag ligand has demonstrated potential as a chemically simple, specific
and orthogonal covalent labeling technique (92), which has recently been coupled with the
SNAP-Tag to create “covalin,” a bifunctional protein capable of heterodimerizing HaloTag
ligand- and BG-tagged proteins (93). HaloTag-based small molecule dimerizer systems
might represent a new experimental direction in the future.
The benefits of using heterobifunctional molecules are clear, from new molecular probes to
selective and specific therapeutics. The next step will be to consider how these molecules
could improve the lives of patients, to push beyond proof-of-principle studies and into whole
organisms, and to see that often two heads are better than one.
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Bifunctional Of a small molecule, having two functionalities, such as binding two
proteins
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(CID)
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Yeast three-
hybrid
A technique used to assay small molecule-protein interactions,
consisting of a DNA binding domain fusion protein, a transcriptional
activation domain fusion protein, and a small molecule that unites
them to activate a transcriptional readout
Multivalent Displaying multiple copies of attachment sites for ligands or other
binding partners
Ubiquitin-
dependent
proteolysis
A mechanism of regulated protein degradation driven by the selective
linkage of the small protein ubiquitin to a target protein, marking it
for destruction by the 26S proteasome
PROTAC PROteolysis TArgeting Chimera, a heterobifunctional molecule that
links a target protein to an E3 ubiquitin ligase, leading to ubiquitin-
dependent proteolysis of the target
Drug hybrid A covalent fusion of two or more existing drugs or pharmacophores
to create a single molecule with multiple, but not necessarily
simultaneous, pharmacological targets
Magic bullet A drug that specifically targets a disease-causing agent, such as a
microorganism, with no side effects on the patient. The term is
attributed to Paul Ehrlich, developer of arsphenamine (Salvarsan), the
first modern chemotherapeutic, which selectively kills the spirochete
that causes syphilis
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Figure 1.
A generic bifunctional molecule brings two protein molecules together to induce a
biological effect.
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Figure 2.
Overview of the yeast three-hybrid technique. A DNA-binding domain (DBD) is fused to
Protein X. A heterobifunctional small molecule binds to Protein X, linking it to Protein Y,
which in turn is fused to a transcriptional activation domain (AD). The presence of the small
molecule brings the two protein fusions together, activating transcription of a reporter gene.
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Figure 3.
Bifunctional molecules used in cell-free studies. Colored shapes represent the regions of
each small molecule that bind to the proteins listed. DHFR, dihydrofolate reductase; PLA2,
phospholipase A2; SAP, serum amyloid P.
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Figure 4.
Bifunctional molecules used in techniques requiring genetic manipulation. Colored shapes
represent the regions of each small molecule that bind to the fusion proteins listed. GFP,
green fluorescent protein; ER, estrogen receptor; DHFR, dihydrofolate reductase; GR,
glucocorticoid receptor.
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Figure 5.
Bifunctional molecules used in techniques that do not require genetic manipulation. Colored
shapes represent the regions of each small molecule that bind to the proteins listed. ER,
estrogen receptor; MetAP-2, methionine aminopeptidase 2; GFP-AR, green fluorescent
protein-androgen receptor; VHL, von Hippel Lindau; AHR, aryl hydrocarbon receptor.
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Figure 6.
Overview of the PROTACS system. A PROTAC molecule brings a target protein into
contact with an E3 ubiquitin ligase, prompting transfer of ubiquitin (Ub) from an E2
ubiquitin conjugating enzyme, leading to polyubiquitination of the target protein and
degradation by the 26S proteasome.
Corson et al. Page 23
ACS Chem Biol. Author manuscript; available in PMC 2010 August 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 7.
Harnessing immune recognition with small molecules. A small molecule ligand for the
target protein (brown), known to be expressed on the cells of interest, is linked to an epitope
that is recognized by endogenous antibodies (purple).
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Figure 8.
Drug hybrids combine two pharmacophores in a single molecule. Functional moieties are
indicated by colored shapes. MAO, monoamine oxidase; GABA, γ-aminobutyric acid.
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